December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

621.91 -1.51 (-0.24%)
Streaming Delayed Price Updated: 3:48 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
63 64 Next >
News headline image
CPI Data Sparks Rally in Biotech Stocks
Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market. 
Via MarketBeat
Topics ETFs Economy
News headline image
Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling ↗
 
Via Benzinga
News headline image
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split ↗
Revenue is climbing at these two drug companies -- and the trend should continue. 
Via The Motley Fool
News headline image
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 ↗
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
Via InvestorPlace
News headline image
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today ↗
 
Via Benzinga
News headline image
Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
Healthcare Stocks Continue To Lag The Market-Can Anything Help ? ↗
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
News headline image
3 No-Brainer Stocks to Buy in July ↗
Investors shouldn't have to think too hard about these great stocks. 
Via The Motley Fool
News headline image
3 Pharma Stocks Already Ushering in the Next Biotech Boom ↗
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider. 
Via InvestorPlace
News headline image
The 3 Best Biotech Stocks to Buy in July 2024 ↗
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024. 
Via InvestorPlace
News headline image
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
News headline image
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $10,000 Today ↗
 
Via Benzinga
News headline image
7 High Priced Stocks That Would Benefit From a Stock Split ↗
These companies are prime stock split candidates following moves from Nvidia and Broadcom along with other big names. 
Via InvestorPlace
News headline image
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data ↗
EMA approves Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled COPD characterized by raised blood eosinophils. This marks the first new treatment for COPD in over a... 
Via Benzinga
News headline image
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What's Going On With Regeneron Pharmaceuticals Stock On Friday? ↗
Regeneron Pharmaceuticals received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for conditional approval of odronextamab. Final decision... 
Via Benzinga
News headline image
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in both relapsed/refractory follicular lymphoma and diffuse large B-cell... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product ↗
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales. 
Via Benzinga
News headline image
3 Biotech Stocks That Could Make Your Grandchildren Rich ↗
These biotech stocks are poised to generate significant returns to investors due to their high growth potential. 
Via InvestorPlace
News headline image
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs ↗
Regeneron Pharmaceuticals released data from a Phase 1 study on garetosmab and trevogrumab at the ADA meeting, showing significant increases in lean mass and reductions in fat mass in healthy... 
Via Benzinga
News headline image
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More ↗
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
Via Benzinga
News headline image
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
News headline image
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for June 2024 ↗
Investors looking for companies with high growth potential should consider investing in these three strong buy Cathie Wood stocks. 
Via InvestorPlace
News headline image
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market ↗
Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market. 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
63 64 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.